6533b7d8fe1ef96bd126996b
RESEARCH PRODUCT
Effect of low-dose aspirin on health outcomes: An umbrella review of systematic reviews and meta-analyses.
Stefano CelottoGabriella PesolilloNicola VeroneseLee SmithIoanna TzoulakiIoanna TzoulakiJoseph FirthJoseph FirthMarco SolmiAlberto VaonaTommaso BarniniGraziano OnderStefania MaggiJohn P. A. IoannidisBrendon StubbsBrendon StubbsAlberto PilottoAi KoyanagiAi KoyanagiJacopo DemurtasTrevor ThompsonEvropi TheodoratouEvropi Theodoratousubject
medicine.medical_specialtyPopulationLower riskPlacebo030226 pharmacology & pharmacySystematic Reviews and Meta‐analysisRisk Assessmentlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansPharmacology (medical)aspirin cancer cardiovascular disease meta-analysis umbrella review030212 general & internal medicineeducationPharmacologyAspirineducation.field_of_studyAspirinbusiness.industrytechnology industry and agriculturemedicine.diseaseMeta-analysisObservational studylipids (amino acids peptides and proteins)Upper gastrointestinal bleedingbusinessGastrointestinal Hemorrhagemedicine.drugdescription
Aims:\ud \ud This study aimed to use an umbrella review methodology to capture the range of outcomes that were associated with low‐dose aspirin and to systematically assess the credibility of this evidence.\ud \ud Methods:\ud \ud Aspirin is associated with several health outcomes, but the overall benefit/risk balance related to aspirin use is unclear. We searched three major databases up to 15 August 2019 for meta‐analyses of observational studies and randomized controlled trials (RCTs) including low‐dose aspirin compared to placebo or other treatments. Based on random‐effects summary effect sizes, 95% prediction intervals, heterogeneity, small‐study effects and excess significance, significant meta‐analyses of observational studies were classified from convincing (class I) to weak (class IV). For meta‐analyses of RCTs, outcomes with random effects P ‐value < .005 and a moderate/high GRADE assessment, were classified as strong evidence. From 6802 hits, 67 meta‐analyses (156 outcomes) were eligible.\ud \ud Results:\ud \ud Observational data showed highly suggestive evidence for aspirin use and increased risk of upper gastrointestinal bleeding (RR = 2.28, 95% CI: 1.97–2.64). In RCTs of low‐dose aspirin, we observed strong evidence for lower risk of CVD in people without CVD (RR = 0.83; 95% CI: 0.79–0.87) and in general population (RR = 0.83; 95% CI: 0.79–0.89), higher risk of major gastrointestinal (RR = 1.47; 95% CI: 1.26–1.72) and intracranial bleeding (RR = 1.34; 95% CI: 1.18–1.53), and of major bleedings in people without CVD (RR = 1.62; 95% CI: 1.26–2.08).\ud \ud Conclusion:\ud \ud Compared to other active medications, low‐dose aspirin had strong evidence for lower risk of bleeding, but also lower comparative efficacy. Low‐dose aspirin significantly lowers CVD risk and increases risk of bleeding. Evidence for multiple other health outcomes is limited.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-06-02 |